Short answer
Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events). Convertible Notes issued privately under Securities Act Section 4(a)(2), restricting resale absent registration or exemption.
Syndax Pharmaceuticals Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Convertible Notes issued privately under Securities Act Section 4(a)(2), restricting resale absent registration or exemption
- Maximum 13,631,400 common shares issuable upon conversion, creating potential shareholder dilution
- Initial conversion rate 54.5256 shares per $1,000 principal, subject to customary anti-dilution adjustments
- Conversion shares expected to qualify for Section 3(a)(9) registration exemption with no commissions or remuneration anticipated
Item 8.01 · Other Events
- Notes pricing announced June 4, 2026, signaling completed financing terms and upcoming capital access
- Net proceeds intended for company purposes, with allocation details in Exhibit 99.1
- Financing introduces potential dilution or repayment obligations, depending on the Notes’ structure
- Investors should review Exhibit 99.1 for principal amount, conversion terms, interest rate, maturity, and proceeds use
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Syndax Pharmaceuticals Inc 8-K filings
Get the next SNDX 8-K as it lands
Follow SNDX for push alerts, or ask the research agent what this filing means.